Streetbeat News

IYH

iShares U.S. Healthcare ETF

https://www.ishares.com/us/products/239511/ishares-us-healthcare-etf

Industry

Asset Management

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

Open

60.64

Mkt cap

657M

Volume

839K

High

60.64

P/E Ratio

4.87

52-wk high

66.59

Low

59.68

Div yield

0.01

52-wk low

53.37

The Global Data report indicates a decrease in pharma sector M&A deals in Q3 2023 compared to Q2 2023, with a 28% drop in deal value and a 9% drop in deal volume. However, PricewaterhouseCoopers forecasts a positive outlook for 2024, expecting a return to pre-pandemic levels of M&A activity. Notable deals in 2023 include acquisitions by Pfizer, Bristol Myers Squibb, Merck, AbbVie, Biogen, and Astellas Pharma.

Portfolio Pulse from Vandana Singh

December 29, 2023 | 12:04 pm

On CNBC's 'Halftime Report Final Trades,' Shake Shack CEO Randy Garutti announced his retirement in 2024, with the company expecting Q4 revenue in line with consensus. Humana was highlighted for its earnings multiple, while Cigna ended acquisition talks with Humana over price disagreements. Pfizer was noted for its high dividend yield and its donation of Bavencio royalties to address FTC concerns regarding its acquisition of Seagen, which is expected to close on Dec. 14. The iShares U.S. Healthcare ETF was also picked, with all mentioned stocks and ETFs experiencing gains in the last session.

Portfolio Pulse from Avi Kapoor

December 13, 2023 | 1:22 pm

Cigna Corporation (NYSE:CI) has decided to abandon its proposed merger with Humana Inc. (NYSE:HUM) due to disagreements over financial terms. Instead, Cigna is shifting its focus to smaller acquisitions and has announced a $10 billion stock buyback program, increasing its total planned buybacks to $11.3 billion. The company remains positive about the benefits of a partnership with Humana and plans to repurchase at least $5 billion of common stock by mid-2024. The collapse of the deal leaves Cigna evaluating the sale of its Medicare Advantage business while continuing to expand its Evernorth health services unit.

Portfolio Pulse from Bibhu Pattnaik

December 10, 2023 | 7:00 pm

On CNBC's 'Halftime Report Final Trades,' experts shared their final trades, including iShares U.S. Healthcare ETF (IYH), Comerica Incorporated (CMA), Cleveland-Cliffs Inc. (CLF), and Humana Inc. (HUM). Goldman Sachs analyst Ryan Nash maintained a Neutral rating on Comerica and raised the price target from $45 to $50. Cleveland-Cliffs announced price increases for steel products last month. Humana closed higher on Friday amid reports of a potential merger with Cigna Group. Comerica, iShares U.S. Healthcare ETF, Cleveland-Cliffs, and Humana all saw share price increases on Friday.

Portfolio Pulse from Lisa Levin

December 04, 2023 | 1:53 pm

On CNBC's 'Halftime Report Final Trades,' experts discussed their views on several stocks and an ETF. Shannon Saccocia of Boston Private expects a rotation back into the healthcare sector and named iShares U.S. Healthcare ETF (IYH). Rob Sechan of NewEdge Wealth highlighted Broadcom Inc. (AVGO) for its low valuation and high operating margin, noting its acquisition of VMware. Jim Lebenthal of Cerity Partners believes Cisco Systems, Inc. (CSCO) is poised for recovery despite a bad week and lowered projections for 2024. Joseph Terranova of Virtus Investment Partners chose Burlington Stores, Inc. (BURL), which reported a revenue miss in Q3. Broadcom shares fell, Cisco shares rose, Burlington gained, and the iShares U.S. Healthcare ETF also saw gains in Wednesday's session.

Portfolio Pulse from Lisa Levin

November 24, 2023 | 1:23 pm

The FDA has proposed a regulatory shift that would require lab-developed tests to be reviewed before they can be sold. This move has created uncertainty in the laboratory-testing market, potentially affecting startups that are developing tests to detect diseases earlier and personalize treatments. The FDA's concerns are based on the efficacy of lab-developed tests, which have led to over- or under-treatment for heart disease, inappropriate therapies, and incorrect diagnoses of diseases, including Alzheimer's.

Portfolio Pulse from Vandana Singh

October 05, 2023 | 1:06 pm

The article discusses the current financial conditions, focusing on the rise in 10-year Treasuries and real 10s. It also highlights the impact of the yuan and yen exchange rate weakness on the continuation of the real rate bear yield curve steepening. The article further discusses the potential risks and opportunities in the banking and energy sectors, and the impact of deglobalization on productivity. It concludes with a tactical asset allocation recommendation.

Portfolio Pulse from Barry Knapp

August 24, 2023 | 7:28 pm

New York psychologist, Dr. Junhong Cao, has highlighted the potential of the ancient Chinese concept of 'wu wei' or 'action through inaction' as a counterbalance to modern day stress and burnout. She suggests that companies and investors in the mental well-being and health sectors, such as Johnson & Johnson, Pfizer Inc., and ETFs like the Health Care Select Sector SPDR Fund and the iShares U.S. Healthcare ETF, could find value in these perspectives.

Portfolio Pulse from Bibhu Pattnaik

August 17, 2023 | 1:27 pm

Goldman Sachs research suggests the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This comes as patents for some blockbuster drugs are nearing expiration. Recent examples include Astellas Pharma acquiring Iveric Bio, Pfizer proposing to acquire Seagen, GSK agreeing to acquire BELLUS Health, and Merck announcing to acquire Prometheus Biosciences. The healthcare sector had a challenging start to 2023 due to regulatory & growth concerns, macroeconomic rotations, and investor preference for large-cap technology stocks.

Portfolio Pulse from Vandana Singh

July 07, 2023 | 5:18 pm

White House Press Secretary stated that there is nothing in the Constitution preventing Medicare from negotiating lower drug prices, potentially impacting pharmaceutical companies and healthcare providers.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2023 | 5:13 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.